Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats

Journal of Hypertension

Volumn 28, Issue 11, 2010, Pages 2278-2288

  Ito, Daisuke ^a   Ito, Osamu ^a   Mori, Nobuyoshi ^a   Muroya, Yoshikazu ^a   Cao, Peng Yu ^a   Takashima, Kenta ^a   Kanazawa, Masayuki ^a   Kohzuki, Masahiro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; hypertension; nitric oxide synthases; Rho kinase; spontaneously hypertensive rat; statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZRIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MOESIN; NEURONAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; RADIXIN; RHO KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HYPERTENSION; IMMUNOBLOTTING; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

EID: 77958462484     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833e0924     Document Type: Article

References (46)

1. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49:792-798. (Pubitemid 351664226)
2. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta analysis. J Am Soc Nephrol 2006; 17:2006-2016.
3. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30:968-974.
4. Bezerra DG, Mandarium-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci 2005; 108: 349-355.
5. Wassmann S, Laufs U, Bäumer AT, Müller K,Ahlbory K,Linz W, etal. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37:1450-1457.
6. Kishi T, Hirooka Y, Mukai Y, Shimokawa H, Takeshita A. Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats. J Hypertens 2003; 21:379-386.
7. O'Donnell MP, Kasiske BL, Katz SA, Schmitz PG, Keane WF. Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 1992; 20:651-658.
8. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44:186-190.
9. Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-b, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 2008; 295:F53-F59.
10. Lee TM, Lin MS, Tsai CH, Chang NC. Effect of pravastatin on left ventricular mass in the two-kidney, one clip hypertensive rats. Am J Physiol Heart Circ Physiol 2006; 291:H2705-H2713.
11. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62:367-374.
12. Harris KP, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990; 15:16-23.
13. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 2005; 45:2-14.
14. Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol 2006; 187:433-446.
15. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1988; 97:1129-1135.
16. Laufs U, Liao JK. Posttranscriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273:24266-24271.
17. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106:57-62.
18. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22:8467-8477.
19. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6:1004-1010.
20. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001; 89:866-873.
21. Nakata S, Tsutsui M, Shimokawa H, Yamashita T, Tanimoto A, Tasaki H, et al. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway. Arterioscler Thromb Vasc Biol 2007; 27:92-98.
22. Uehata M, Ishizuki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389:990-994.
23. Nishikimi T, Koshikawa S, Ishikawa Y, Akimoto K, Inaba C, Ishimura K, et al. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J Hypertens 2007; 25:1053-1063.
24. Luo Z, Fujio Y, Kureishi Y, Rudic RD, Daumerie G, Fulton D, et al. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest 2000; 106:493-499.
25. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, et al. AKT participates in endothelial dysfunction in hypertension. Circulation 2004; 109:2587-2593.
26. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y,Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996; 392:189-193.
27. Yonemura S, Matsui T, Tsukita S, Tsukita S. Rho-dependent and-independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J Cell Sci 2002; 115:2569-2580.
28. Jiang J, Sun C-W, Alonso-Galcia M, Roman RJ. Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. Am J Hypertens 1998; 11:1222-1231.
29. Inman SR, Caprio TW, Drummond E, Mueller M, Entenman K. Enhanced acetylcholine-induced dilation in afferent arterioles in simvastatin-fed rats. Vascular Pharmacol 2006; 44:17-21.
30. Varela M, Garvin JL. Acute and chronic regulation of thick ascending limb endothelial nitric oxide synthase by statins. J Am Soc Nephrol 2004; 15:269-275.
31. Fernandez AP, Serrano J, Castro S, Salazar FJ, Lopez JC, Rodrigo J, Nava E. Distribution of nitric oxide synthases and nitrotyrosine in the kidney of spontaneously hypertensive rats. J Hypertens 2003; 21:2375-2388.
32. Vaziri ND, Ni Z, Oveisi F. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 1998; 31:1248-1254.
33. Gao L, Wang W, Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther 2008; 326:278-285.
34. Inscho EW, Cook AK, Clinton CR, Webb C, Jin L-M. Rho-kinase inhibition reduces pressure-mediated autoregulatory adjustments in afferent arteriolar diameter. Am J Physiol Renal Physiol 2009; 296:F590-F597.
35. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399:597-601.
36. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399:601-605.
37. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284:R1-R12.
38. Sun W, Lee T-S, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY-J. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006; 114:2655-2662.
39. Ortiz PA, Garvin JL. Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 2002; 282:F777-F784.
40. Vieira JM Jr, Rodrigues LT, Mantovani E, Dellê H, Mattar AL, Malheiros DM, et al. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol 2005; 101:82-91.
41. LecianD,Demova H,Lodererova A,Zdychova J, Kluckova H,Teplan V, et al. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res 2006; 29:135-143.
42. Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-indeoendent protective actions against angiotensin II-induced cardiovascular remodeling and renal insufficiency. Circ Res 2008; 102:68-76.
43. Budzyn K, Markey PD, Sobey CG. Chronic mevastatin modulates receptor-dependent vascular contraction in eNOS-deficient mice. Am J Physiol Regul Integr Comp Physiol 2004; 287:R342-R348.
44. Rikitake Y, Liao JK. Rho GTPases, statins and nitric oxide. Circ Res 2005; 97:1232-1235.
45. Löhn M, Steioff K, Bleich M, Busch AE, Ivashchenko Y. Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation. Eur J Pharmacol 2005; 507:179-186.
46. Koshikawa S, Nishiki T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rat. J Hypertens 2008; 26:1837-1848.